The DYNC2H1 Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal cell population designed to disrupt the DYNC2H1 gene in the human A-549 lung adenocarcinoma background. This polyclonal pool avoids the clonal variation of single-cell-derived lines, providing a robust platform for investigating DYNC2H1-dependent processes.
The parental A-549 cell line, established from a human lung carcinoma, serves as a well-characterized model of alveolar basal epithelial adenocarcinoma. Widely utilized for studying lung cancer biology, these cells also form primary cilia under appropriate conditions, making them suitable for examining ciliary signaling and intraflagellar transport in a carcinoma context.
DYNC2H1 encodes the heavy chain subunit of cytoplasmic dynein-2, the motor responsible for retrograde intraflagellar transport (IFT) in primary cilia. The dynein-2 complex, together with light intermediate chains such as DYNC2LI1 and regulators like WDR34, retrograde transports IFT particles and associated cargo, including Hedgehog signaling components. DYNC2H1 functions under the control of transcription factors FOXJ1 and RFX, which drive ciliary gene expression. Its activity is critical for the proper trafficking of SMO, PTCH1, and GLI transcription factors (GLI1, GLI2, GLI3). Following Hedgehog pathway activation, retrograde transport by DYNC2H1 facilitates the processing of GLI proteins, with co-factors SUFU, KIF3A, and IFT88 ensuring signal fidelity. Disruption of DYNC2H1 therefore blocks retrograde IFT, leading to impaired ciliary trafficking and attenuated Hedgehog signaling.
In A-549 cells, where primary cilia are functionally coupled to Hedgehog pathway modulation, DYNC2H1 loss profoundly impacts downstream transcriptional programs. This knockout model allows researchers to dissect the role of ciliary transport in lung adenocarcinoma cell behavior, including effects on proliferation and migration. Furthermore, it offers a tractable human cell system for modeling the cellular defects underlying skeletal ciliopathies such as short-rib polydactyly syndromes and Jeune asphyxiating thoracic dystrophy, by recapitulating conserved ciliary dysfunction.
Applications of these polyclonal knockout cells include western blotting for DYNC2H1 depletion assessment, RT-qPCR of GLI target genes, immunofluorescence visualization of ciliary markers (ARL13B, acetylated tubulin), and Hedgehog luciferase reporter assays. Additional functional assays like cell viability and migration studies provide phenotypic readouts, while the polyclonal format supports drug screening campaigns. For more detailed information and technical support, please contact Ascent Research.
